Lawrence B Schwartz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4492596/publications.pdf

Version: 2024-02-01

36303 37204 9,484 109 51 96 citations g-index h-index papers 110 110 110 5847 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. Journal of Allergy and Clinical Immunology, 2022, 149, 1010-1017.e10.	2.9	38
2	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1999-2012.e6.	3.8	35
3	Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1. Journal of Allergy and Clinical Immunology, 2021, 147, 622-632.	2.9	137
4	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 411.	4.1	21
5	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3918-3928.	3 . 8	33
6	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2139-2144.	3.8	31
7	Clinical relevance of inherited genetic differences in human tryptases. Annals of Allergy, Asthma and Immunology, 2021, 127, 638-647.	1.0	30
8	Mast Cell Activation During Suspected Perioperative Hypersensitivity: A Need for Paired Samples Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3051-3059.e1.	3.8	13
9	Use and Interpretation of Acute and Baseline Tryptase in Perioperative Hypersensitivity and Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2994-3005.	3.8	45
10	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 2021, 5, e646.	2.7	128
11	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. Leukemia and Lymphoma, 2020, 61, 1075-1083.	1.3	11
12	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics, 2020, 10, 10743-10768.	10.0	107
13	Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 104-112.	2,5	6
14	Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma and Immunology, 2020, 125, 334-340.e1.	1.0	4
15	Clinical Approach to a Patient with Elevated Serum Tryptase: Implications of Acute Versus Basally Elevated Levels. , 2020, , 35-54.		3
16	Impact of naturally forming human $\hat{l}\pm/\hat{l}^2$ -tryptase heterotetramers in the pathogenesis of hereditary $\hat{l}\pm$ -tryptasemia. Journal of Experimental Medicine, 2019, 216, 2348-2361.	8.5	85
17	AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. Journal of Allergy and Clinical Immunology, 2019, 144, 883-896.	2.9	72
18	An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma. Cell, 2019, 179, 417-431.e19.	28.9	76

#	Article	IF	Citations
19	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1793-1802.e2.	3.8	58
20	Paired acuteâ€baseline serum tryptase levels in perioperative anaphylaxis: An observational study. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1157-1165.	5.7	49
21	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1125-1133.e1.	3.8	150
22	Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: AÂWork Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. Journal of Allergy and Clinical Immunology, 2019, 143, 880-893.	2.9	50
23	Clinical communication: systemic capillary leak syndrome due to mast cell activation?. Annals of Allergy, Asthma and Immunology, 2019, 122, 428-429.	1.0	0
24	lgE-mediated mast cell activation promotes inflammation and cartilage destruction in osteoarthritis. ELife, 2019, 8, .	6.0	74
25	Dual functionality of \hat{l}^2 -tryptase protomers as both proteases and cofactors in the active tetramer. Journal of Biological Chemistry, 2018, 293, 9614-9628.	3.4	13
26	Human mast cells present antigen to autologous CD4+ T cells. Journal of Allergy and Clinical Immunology, 2018, 141, 311-321.e10.	2.9	52
27	Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks. JAMA - Journal of the American Medical Association, 2018, 320, 2108.	7.4	174
28	Mast cell activation syndrome: Importance of consensus criteria and call for research. Journal of Allergy and Clinical Immunology, 2018, 142, 1008-1010.	2.9	27
29	Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2018, 121, 464-468.e3.	1.0	40
30	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research, 2017, 77, 1261-1270.	0.9	210
31	A Multiparametric Model for Mapping Cellularity in Glioblastoma Using Radiographically Localized Biopsies. American Journal of Neuroradiology, 2017, 38, 890-898.	2.4	90
32	Chronic Idiopathic Urticaria: Systemic Complaints and Their Relationship with Disease and Immune Measures. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1314-1318.	3.8	49
33	Fatal anaphylaxis caused by gadolinium due to beta-tryptase–induced hemorragic diathesis. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1433-1434.	3.8	9
34	A humanized mouse model of anaphylactic peanut allergy. Journal of Allergy and Clinical Immunology, 2017, 139, 314-322.e9.	2.9	54
35	Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis. PLoS ONE, 2016, 11, e0162831.	2.5	9
36	Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nature Genetics, 2016, 48, 1564-1569.	21.4	279

#	Article	IF	CITATIONS
37	Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organization Journal, 2016, 9, 7.	3.5	124
38	Anaphylaxis and Its Management. , 2016, , 651-671.		0
39	Presence or Absence of Elevated Acute Total Serum Tryptase by Itself Is Not a Definitive Marker for an Allergic Reaction. Anesthesiology, 2015, 122, 713-714.	2.5	34
40	Refractory intraoperative hypotension with elevated serum tryptase. Asia Pacific Allergy, 2015, 5, 47-50.	1.3	6
41	Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. Journal of Allergy and Clinical Immunology, 2015, 136, 262-271.e2.	2.9	51
42	Anaphylaxis in America: A national physician survey. Journal of Allergy and Clinical Immunology, 2015, 135, 830-833.	2.9	31
43	Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. Haematologica, 2015, 100, 300-307.	3.5	60
44	A Simple, Sensitive and Safe Method to Determine the Human $\hat{l}\pm/\hat{l}^2$ -Tryptase Genotype. PLoS ONE, 2014, 9, e114944.	2.5	9
45	Contribution of Mast Cell–Derived Interleukinâ€1β to Uric Acid Crystal–Induced Acute Arthritis in Mice. Arthritis and Rheumatology, 2014, 66, 2881-2891.	5.6	59
46	Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity. Journal of Allergy and Clinical Immunology, 2014, 133, 1759-1763.	2.9	80
47	Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States. Journal of Allergy and Clinical Immunology, 2014, 133, 461-467.	2.9	319
48	Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. Journal of Allergy and Clinical Immunology, 2014, 133, 1471-1474.	2.9	110
49	Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis. Blood, 2013, 122, 1779-1788.	1.4	31
50	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood, 2013, 121, 2393-2401.	1.4	122
51	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. International Archives of Allergy and Immunology, 2012, 157, 215-225.	2.1	513
52	Obesity is not linked to increased whole-body mast cell burden in children. Journal of Allergy and Clinical Immunology, 2012, 129, 1164-1166.e4.	2.9	8
53	In Vitro Desensitization of Human Skin Mast Cells. Journal of Clinical Immunology, 2012, 32, 150-160.	3.8	20
54	Total tryptase levels indicate risk for systemic reactions to rush immunotherapy and mast cell activation. Annals of Allergy, Asthma and Immunology, 2011, 106, 342-343.e6.	1.0	8

#	Article	IF	CITATIONS
55	Processing of Human Protryptase in Mast Cells Involves Cathepsins L, B, and C. Journal of Immunology, 2011, 187, 1912-1918.	0.8	26
56	Promiscuous Processing of Human \hat{l}_{\pm}/\hat{l}^2 -Protryptases by Cathepsins L, B, and C. Journal of Immunology, 2011, 186, 7136-7143.	0.8	18
57	Tryptase Is Not Cleared by the Kidneys into the Urine. International Archives of Allergy and Immunology, 2010, 152, 28-31.	2.1	18
58	Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. Journal of Allergy and Clinical Immunology, 2010, 125, 719-726.e4.	2.9	128
59	Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Current Medical Research and Opinion, 2010, 26, 1933-1946.	1.9	15
60	Assessing anaphylactic risk? Consider mast cell clonality. Journal of Allergy and Clinical Immunology, 2009, 123, 687-688.	2.9	53
61	Mast Cells. , 2009, , 31-52B.		0
62	Mast Cells and Basophils. , 2009, , 157-193.		0
63	TGF- \hat{l}^21 Attenuates Mediator Release and De Novo Kit Expression by Human Skin Mast Cells through a Smad-Dependent Pathway. Journal of Immunology, 2008, 181, 7263-7272.	0.8	40
64	Generation of Anaphylatoxins by Human \hat{l}^2 -Tryptase from C3, C4, and C5. Journal of Immunology, 2008, 180, 6307-6316.	0.8	92
65	Omalizumab Reverses the Phenotypic and Functional Effects of IgE-Enhanced FclµRI on Human Skin Mast Cells. Journal of Immunology, 2007, 179, 1353-1361.	0.8	70
66	Active monomers of human \hat{l}^2 -tryptase have expanded substrate specificities. International Immunopharmacology, 2007, 7, 1900-1908.	3.8	24
67	Risk assessment in anaphylaxis: Current and future approaches. Journal of Allergy and Clinical Immunology, 2007, 120, S2-S24.	2.9	237
68	Tryptase haplotype in mastocytosis: Relationship to disease variant and diagnostic utility of total tryptase levels. Clinical Immunology, 2007, 123, 268-271.	3.2	40
69	Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis. Immunology and Allergy Clinics of North America, 2006, 26, 451-463.	1.9	376
70	Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis. Inflammation and Allergy: Drug Targets, 2006, 5, 61-77.	1.8	76
71	Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leukemia and Lymphoma, 2006, 47, 897-906.	1.3	11
72	The B12 Anti-Tryptase Monoclonal Antibody Disrupts the Tetrameric Structure of Heparin-Stabilized \hat{I}^2 -Tryptase to Form Monomers That Are Inactive at Neutral pH and Active at Acidic pH. Journal of Immunology, 2006, 176, 3165-3172.	0.8	30

#	Article	IF	CITATIONS
73	Analysis of MC(T) and MC(TC) mast cells in tissue. Methods in Molecular Biology, 2006, 315, 53-62.	0.9	26
74	Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. Journal of Allergy and Clinical Immunology, 2005, 115, 1162-1168.	2.9	133
75	Human β-Tryptase:  Detection and Characterization of the Active Monomer and Prevention of Tetramer Reconstitution by Protease Inhibitors. Biochemistry, 2004, 43, 10757-10764.	2.5	35
76	Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non–mast cell hematopoietic neoplasms. Journal of Allergy and Clinical Immunology, 2004, 114, 3-11.	2.9	157
77	Effect of sex and haplotype on plasma tryptase levels in healthy adults. Journal of Allergy and Clinical Immunology, 2004, 114, 48-51.	2.9	40
78	Expression of \hat{l} ±-tryptase and \hat{l} 2-tryptase by human basophils. Journal of Allergy and Clinical Immunology, 2004, 113, 1086-1092.	2.9	97
79	Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders Blood, 2004, 104, 4754-4754.	1.4	0
80	Effector cells of anaphylaxis: mast cells and basophils. Novartis Foundation Symposium, 2004, 257, 65-74; discussion 74-9, 98-100, 276-85.	1.1	15
81	Immunological characterization of A2B adenosine receptors in human mast cells. Drug Development Research, 2003, 58, 461-471.	2.9	16
82	Tryptase Precursors Are Preferentially and Spontaneously Released, Whereas Mature Tryptase Is Retained by HMC-1 Cells, Mono-Mac-6 Cells, and Human Skin-Derived Mast Cells. Journal of Immunology, 2003, 170, 5667-5673.	0.8	107
83	Association of Transient Dermal Mastocytosis and Elevated Plasma Tryptase Levels with Development of Adverse Reactions after Treatment of Onchocerciasis with Ivermectin. Journal of Infectious Diseases, 2002, 186, 1307-1313.	4.0	24
84	Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase. Journal of Allergy and Clinical Immunology, 2002, 109, 82-88.	2.9	52
85	Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils. Journal of Allergy and Clinical Immunology, 2002, 109, 287-293.	2.9	67
86	Human mouse mast cell protease 7–like tryptase genes are pseudogenes. Journal of Allergy and Clinical Immunology, 2001, 107, 315-321.	2.9	18
87	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood, 2001, 98, 2200-2209.	1.4	130
88	Human skin–derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. Blood, 2001, 97, 2045-2052.	1.4	133
89	Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leukemia Research, 2001, 25, 553-562.	0.8	95
90	Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Research, 2001, 25, 603-625.	0.8	1,020

#	Article	IF	Citations
91	Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood, 2000, 96, 1267-1273.	1.4	68
92	Identification and characterization of multiple forms of tryptase from human mast cells. Archives of Dermatological Research, 1999, 291, 73-80.	1.9	13
93	Serum tryptase: an indicator of anaphylaxis following fluorescein angiography. Graefe's Archive for Clinical and Experimental Ophthalmology, 1999, 237, 433-434.	1.9	12
94	Mast cell tryptase does not alter matrix metalloproteinase expression in human dermal fibroblasts: Further evidence that proteolytically-active tryptase is a potent fibrogenic factor., 1999, 181, 312-318.		13
95	The potential clinical utility of serum α-protryptase levels. Journal of Allergy and Clinical Immunology, 1999, 103, 1092-1099.	2.9	61
96	Immunocytochemical Localization of Chymase to Cytoplasmic Vesicles After Rat Peritoneal Mast Cell Stimulation by Compound 48/80. Journal of Histochemistry and Cytochemistry, 1997, 45, 1379-1391.	2.5	10
97	Hymenoptera sting anaphylaxis and urticaria pigmentosa: Clinical findings and results of venom immunotherapy in ten patientsa †a †a †a ta journal of Allergy and Clinical Immunology, 1997, 100, 11-15.	2.9	128
98	Expression and Purification of Recombinant Human Tryptase in a Baculovirus System. Protein Expression and Purification, 1996, 7, 67-73.	1.3	25
99	Treatment of Three Patients with Systemic Mastocytosis with Interferon Alpha-2b. Leukemia and Lymphoma, 1996, 22, 501-508.	1.3	83
100	Immunoelectron microscopic localization of galectin-3, an IgE binding protein, in human mast cells and basophils. The Anatomical Record, 1995, 242, 211-219.	1.8	47
101	Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis. Journal of Clinical Immunology, 1994, 14, 190-204.	3.8	257
102	[6] Tryptase: A mast cell serine protease. Methods in Enzymology, 1994, 244, 88-100.	1.0	76
103	Mast cell changes in scleroderma. Arthritis and Rheumatism, 1992, 35, 933-939.	6.7	66
104	Synovial fluid levels of complement SC5bâ€9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1991, 34, 1531-1537.	6.7	108
105	Laboratory Investigation of Deaths Due to Anaphylaxis. Journal of Forensic Sciences, 1991, 36, 857-865.	1.6	216
106	Interactions of human mast cell tryptase with biological protease inhibitors. Archives of Biochemistry and Biophysics, 1990, 276, 26-31.	3.0	94
107	Tryptase and chymase, markers of distinct types of human mast cells. Immunologic Research, 1989, 8, 130-148.	2.9	70
108	Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis. New England Journal of Medicine, 1987, 316, 1622-1626.	27.0	737

#	ARTICLE	IF	CITATIONS
109	Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. Arthritis and Rheumatism, 1986, 29, 956-963.	6.7	124